Aurora Cannabis tells shareholders: don't sell to Curaleaf

Aurora Cannabis's board came back with a unanimous no on September 15, telling shareholders not to tender their shares into Curaleaf's hostile bid and urging anyone who already had to pull them back. It's the clearest signal yet that Aurora intends to fight this one out rather than negotiate a sweetened offer.

The board's case leans hard on the balance sheet: Aurora says it's debt-free with a healthy cash position, while Curaleaf is carrying more than $1 billion in debt, including $500 million in senior secured notes at 11.5% interest. Aurora also argues the bid undervalues its international medical business — European manufacturing and cultivation Curaleaf doesn't have an easy substitute for.

Aurora's also taken the fight to regulators, filing a complaint with the Alberta Securities Commission on September 2 over what it calls deficiencies in how Curaleaf structured the offer, and says Curaleaf still hasn't addressed those concerns as of this week.

This is round two of a fight that started August 11, when Curaleaf skipped Aurora's board entirely and pitched shareholders directly on an all-stock-and-cash offer. A formal no from the board doesn't end a hostile bid — it just means the next move is Curaleaf's, whether that's sweetening the offer, taking it to a shareholder vote regardless, or walking away.

For MSOs watching from the sidelines, this is a live test of whether a debt-free balance sheet is actually worth a takeover premium in this market, or whether a buyer with Curaleaf's scale can grind out a deal anyway.